Moderna, Inc. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-03-01

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2021-03-01	Common Stock	M	5000	$14.22	Acquired	10000	Direct
2021-03-01	Common Stock	S	2201	$146.68	Disposed	7799	Direct
2021-03-01	Common Stock	S	1986	$147.71	Disposed	5813	Direct
2021-03-01	Common Stock	S	700	$149.00	Disposed	5113	Direct
2021-03-01	Common Stock	S	1039	$149.79	Disposed	4074	Direct
2021-03-01	Common Stock	S	600	$150.86	Disposed	3474	Direct
2021-03-01	Common Stock	S	900	$152.01	Disposed	2574	Direct
2021-03-01	Common Stock	S	753	$154.34	Disposed	1821	Direct
2021-03-01	Common Stock	S	600	$155.69	Disposed	1221	Direct
2021-03-01	Common Stock	S	771	$156.49	Disposed	450	Direct
2021-03-01	Common Stock	S	450	$157.29	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-01	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-02-23	Common Stock (5000)	Direct
2021-03-01	Stock Option (Right to Buy)	$14.22	M	5000	Disposed	2028-02-28	Common Stock (5000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.31 to $147.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.32 to $148.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.33 to $149.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.34 to $150.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.59 to $151.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.73 to $152.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.99 to $154.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.10 to $155.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.13 to $157.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.20 to $157.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F12: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

F13: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.